FDA Grants Groundbreaking Approval to PranaQ’s TipTraQ for AI-Powered Sleep Apnea Diagnosis
PranaQ, a leader in AI-powered sleep diagnostics, has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for TipTraQ, an advanced home sleep apnea test wearable.
This device provides detailed sleep and respiratory insights while ensuring minimal disruption to sleep patterns.
The approval marks a significant step forward in improving access to sleep diagnostics. Millions of individuals remain undiagnosed with sleep apnea, and TipTraQ aims to offer a convenient, accurate, and accessible solution.
With this clearance, PranaQ is preparing to introduce the device across the United States, making it available to sleep clinics, telehealth providers, and hospitals.
TipTraQ is a compact wearable designed to detect sleep apnea events and analyse sleep structure using AI-driven algorithms. With clinical-grade accuracy, it allows individuals to undergo testing in their own homes, reducing obstacles to diagnosis and increasing patient compliance.
The device includes a charging case and enables remote data transfer, eliminating the need for patients to return it after each use. This feature supports multi-night testing and continuous treatment monitoring, offering healthcare providers a comprehensive overview of a patient's sleep patterns over time.
Additionally, TipTraQ identifies sleep apnea severity levels based on established clinical guidelines, ensuring reliable and actionable insights for medical professionals.
The device has demonstrated high sensitivity and specificity in comparison to standard polysomnography (PSG) tests, reinforcing its reliability in detecting sleep apnea. Furthermore, it has been proven to provide consistent oxygen saturation (SpO₂) measurements across various skin tones, addressing challenges commonly associated with pulse oximetry.
By integrating AI-driven analysis into a user-friendly wearable, TipTraQ enhances early detection and simplifies access to sleep apnea testing.
This development is expected to support timely diagnosis and treatment, ultimately improving health outcomes for individuals with sleep-related disorders.